In Veritas Medical Diagnostics Ltd. Lists on Frankfurt Stock Exchange

Market Wire, October, 2006

IVMD Inc., one of the leading developers of novel, physical measurement techniques for in vitro diagnostic products (OTCBB: IVME) proudly announces that its common shares are now also listed on the Frankfurt Stock Exchange under the ticker symbol I7V.F

The CFO Martin Thorp stated, "This listing on the Frankfurt Stock Exchange should help us gain visibility and support in the European market and is part of our long term objective of becoming a global enterprise."

"This is a major step towards furthering the objectives of improving our visibility with the investment community and increasing investor awareness globally. Listing on the Frankfurt exchange will increase the profile of IVMD Inc. with both private and institutional investors in Germany and across Europe. This opportunity to broaden our shareholder base comes at an excellent time for our company as we move into the next phase of our corporate growth strategy," stated Martin Thorp, CFO.

Trading both on the OTC Bulletin Board and on the Frankfurt Stock Exchange may help IVMD Inc. build a better investor foundation to move forward. The Frankfurt Stock Exchange provides full-service trading capabilities, which include a trading floor as well as an electronic trading exchange, XETRA. This new listing will not dilute IVMD's shares.

About the Frankfurt Stock Exchange

The Frankfurt Stock Exchange, known as the Frankfurter Wertpapierborse (FWB) is one of the world's largest trading centers for securities. Operated by the Deutsche Borse AG, FWB is the largest of the eight German stock exchanges. The Deutsche Borse's products and services portfolio cover the entire process chain including securities and derivatives trading, transaction settlement, the provision of market information, as well as the development and operation of electronic trading systems. For more information, visit the Deutsche Borse at: http://deutsche-boerse.com .

About IVMD, Inc.

IVMD uses its proven, patented core technology to design, develop and test medical devices for near patient testing and monitoring. IVMD products serve large global markets in the monitoring of chronic conditions affecting large numbers of the population: the coagulation of blood in patients with cardiovascular disorders, pregnancy (advanced prediction of the onset of human labour), highly sensitive immunoassays, etc. From across all sectors of industry, the company uses proprietary technology to create rapid prototype and product development, in partnership with major global marketing and distribution partners. For more information, visit IVMD Inc. at: http://ivmd.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe,'' "expects,'' "projects,'' "forecasts,'' "intends,'' "will,'' "anticipated,'' "could,'' or "may,'' and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

Contact: IVMD (UK) Ltd. In the UK info@ivmd.com 44(0)1463 667347